Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
07/29/2008
Trade Name:
Cancidas
Generic or Proper Name (*):
caspofungin
Indications Studied:
Empirical therapy for presumed fungal infections in febrile, neutropenic patients; Candidemia and certain Candida infections; Esophageal Candidiasis; Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies
Therapeutic Category:
Antifungal
Ages Studied:
3 months - 17 years
Study #:
4
Study Type:
Efficacy/Safety/Tolerability
Study Design:
Open Label
No Patients:
49
No Centers:
12
No Countries:
5
BPCA(B), PREA(P):
B, P
Asian:
9
Black:
6
Other:
2
White:
30
Native Hawaiian or Pacific Islander:
2
American Indian/Alaska Native:
0
Hispanic/Latino:
0
Non-Hispanic/Non Latino:
0
-
-